VTGN has been in the news 450% more than usual
Feb 05, 2026, 11:34 AM
14.82%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
VTGN has been in the news recently: Levi & Korsinsky and Schall Law have filed class-action lawsuits against Vistagen Therapeutics (VTGN), alleging the company misled investors about Phase 3 PALISADE-2 results for purchasers from April 1, 2024 to December 16, 2025.
During that period Vistagen’s shares fell from $4.36 to $0.86 (about an 80% decline), and the deadline to join the class actions is March 16, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.